Newpath Partners — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Myeloid Therapeuticsmyeloidtx.comin𝕏May 2026 · $122M
CREATE Medicines develops in vivo CAR immunotherapy using proprietary mRNA-LNP technology to program T cells, NK cells, and myeloid cells directly within the body for cancer, autoimmunity, and fibrosis.
AI & Machine LearningBiotechHealthtechMedical Devices
Co-investorsARCH Venture Partners8VCHatteras Venture Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.